Login to Your Account

Clinic Roundup

Thursday, January 26, 2012
• Gilead Sciences Inc., of Foster City, Calif., said it started a Phase II trial of GS-7430, a prodrug of tenofovir, the active agent in Viread (tenofovir disoproxil fumarate), in HIV-1 infection in treatment-naïve adults. The study will evaluate GS-7340 as part of a once-daily, co-formulated single-tablet regimen that will also contain the boosting agent cobicistat, the integrase inhibitor elvitegravir and Emtriva (emtricitabine) and will compare that regimen to Gilead's Quad single-tablet regimen containing Viread and Emtriva (as Truvada), elvitegravir and cobicistat.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription